US Stock MarketDetailed Quotes

ELUT Elutia

Watchlist
  • 4.840
  • +1.310+37.11%
Close Dec 20 16:00 ET
  • 4.740
  • -0.100-2.07%
Post 19:46 ET
167.28MMarket Cap-2.42P/E (TTM)

About Elutia Company

Elutia, Inc. operates as a biotechnology company. It develops biologic products to improve compatibility between medical devices and the patients who need them. The firm operates through the following segments: Device Protection, Women’s Health, Orthobiologics and Cardiovascular. The Device Protection segment includes biological envelope that remodels into systematically connected, vascularized tissue for the long-term pocket protection of certain cardiac and neurostimulator implantable electronic vehicles. The Women’s Health segment includes pre-hydrated, human acellular dermal matrix, or HADM, that is designed to enable rapid integration, cellular repopulation and rapid revascularization at the surgical site. The Orthobiologics segment includes a variety of viable matrices, produced with a proprietary process that is designed to protect and preserve native bone cells and reduce programmable cell death, for use in bone repair and fusion procedures. The Cardiovascular segment includes a portfolio of extracellular matrices that retain the natural composition of collagen, growth factors and proteins for use in vascular and cardiac repair and pericardial closure. The company was founded by Kevin L. Rakin and Charles Randal Mills on August 6, 2015 and is headquartered in Silver Spring, MD.

Company Profile

SymbolELUT
Company NameElutia
Listing DateOct 8, 2020
Founded2015
CEODr. C. Randal Mills, PhD
MarketNASDAQ
Employees54
Fiscal Year Ends12-31
Address12510 Prosperity Drive,Suite 370
CitySilver Spring
ProvinceMaryland
CountryUnited States of America
Zip Code20904
Phone1-240-247-1147

Company Executives

  • Name
  • Position
  • Salary
  • Dr. C. Randal Mills, PhD
  • Director, Chief Executive Officer and President
  • 2.05M
  • Dr. Michelle Leroux Willia PhD
  • Chief Scientific Officer
  • 485.97K
  • Matthew B. Ferguson
  • Chief Financial Officer and Principal Accounting Officer
  • 521.08K
  • Kevin Rakin
  • Executive Chairman of the Board
  • 254.61K
  • William Matthew Zuga
  • Director
  • 80.99K
  • Maybelle Jordan
  • Independent Director
  • 96.41K
  • Brigid A. Makes
  • Independent Director
  • 116.41K
  • David Colpman
  • Independent Director
  • 93.91K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.